Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...
Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors
Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...
Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices
Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals...
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...
Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss Results in Phase I Trial
Terns Pharmaceuticals Inc. (NASDAQ: TERN), a U.S.-based biotechnology company originally spun out from Eli Lilly’s...
GSK’s Nucala Shows Promise in Phase III COPD Trial, MATINEE Results Positive
GSK plc (LON: GSK, NYSE: GSK), a leading UK-based pharmaceutical company, has announced positive results...
US House Approves Biosecure Act with Implications for Chinese Biotech Firms
The US House of Representatives has taken a decisive step towards tightening biosecurity measures, voting...
CIRC’s Subsidiary HTA Co., Ltd. Secures NMPA Approval for Sodium Fluoride [18F] for Bone Imaging
China Isotope & Radiation Corporation’s (CIRC) subsidiary, HTA Co., Ltd. (HKG: 1763), has announced that...
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Beijing Centergate Technologies and Bestcomm Pharmaceutical Form Strategic Partnership in Multiple Medical Fields
Beijing Centergate Technologies (Holding) Co., Ltd (CENTEK, SHE: 000931), a pharmaceutical manufacturing company in China,...
Jiangsu Hengrui’s ANGPTL3 Inhibitor SHR-1918 Earns Breakthrough Designation for HoFH Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...
JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development
JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200...
Amoy Diagnostics’ AiHuiJie Lung Cancer Companion Diagnostic Receives NMPA Approval
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a biopharmaceutical company based in China, has announced...
AstraZeneca and Daiichi Sankyo’s Dato-DXd Misses Overall Survival Endpoint but Shows Promise in NSCLC Subgroup
AstraZeneca (NASDAQ: AZN) and its co-development partner, Japan’s Daiichi Sankyo, have released data from the...
Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development
Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S....
Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial
Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645), a biotechnology company based in China,...
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...
NHC Releases Updated List of Pediatric Drugs for Research and Development Incentives
The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric...
Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...